Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

NCT00219362 is registered in ClinicalTrials.gov with Objectif Recherche Vaccins SIDA as lead sponsor.

NCT NCT00219362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients
Lead sponsor
Objectif Recherche Vaccins SIDA
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
September 30, 2006
Enrollment
65 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection